Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Inventory: 2023-2025

Historic Inventory for BioLineRx (BLRX) over the last 1 years, with Jun 2025 value amounting to $2.9 million.

  • BioLineRx's Inventory fell 21.57% to $2.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.9 million, marking a year-over-year decrease of 21.57%. This contributed to the annual value of $3.1 million for FY2024, which is 61.03% up from last year.
  • Per BioLineRx's latest filing, its Inventory stood at $2.9 million for Q2 2025, which was down 14.03% from $3.3 million recorded in Q1 2025.
  • BioLineRx's 5-year Inventory high stood at $3.6 million for Q2 2024, and its period low was $1.4 million during Q3 2023.
  • Over the past 3 years, BioLineRx's median Inventory value was $3.0 million (recorded in 2024), while the average stood at $2.8 million.
  • As far as peak fluctuations go, BioLineRx's Inventory soared by 162.13% in 2024, and later declined by 21.57% in 2025.
  • Quarterly analysis of 3 years shows BioLineRx's Inventory stood at $2.0 million in 2023, then spiked by 61.03% to $3.1 million in 2024, then declined by 21.57% to $2.9 million in 2025.
  • Its Inventory stands at $2.9 million for Q2 2025, versus $3.3 million for Q1 2025 and $3.1 million for Q4 2024.